The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …

Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …

Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose
incidence is increasing. Largely neglected for decades as a rare malignancy and frequently …

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …

Recent advances in understanding the roles of immune checkpoints in allowing tumors to
circumvent the immune system have led to successful therapeutic strategies that have …

Background CD8+ T cells differentiate into exhausted status within tumors, including
hepatocellular carcinoma (HCC), which constitutes a solid barrier to effective anti-tumor …